A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

RET fusions are oncogenic drivers of various tumors, including non-small cell lung cancers (NSCLCs). The safety and antitumor activity of the multikinase RET inhibitor RXDX-105 were explored in a phase I/Ib trial. A recommended phase 2 dose of 275 mg fed daily was identified. The most common treatme...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Discov
Hlavní autoři: Drilon, Alexander, Fu, Siqing, Patel, Manish R., Fakih, Marwan, Wang, Ding, Olszanski, Anthony J., Morgensztern, Daniel, Liu, Stephen V., Cho, Byoung Chul, Bazhenova, Lyudmila, Rodriguez, Cristina P., Doebele, Robert C., Wozniak, Antoinette, Reckamp, Karen L., Seery, Tara, Nikolinakos, Petros, Hu, Zheyi, Oliver, Jennifer W., Trone, Denise, McArthur, Katherine, Patel, Rupal, Multani, Pratik S., Ahn, Myung-Ju
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6397691/
https://ncbi.nlm.nih.gov/pubmed/30487236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0839
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky